Genetic immune escape landscape in primary and metastatic cancer

DSpace/Manakin Repository

Genetic immune escape landscape in primary and metastatic cancer
 
Martínez-Jiménez, Francisco; Priestley, Peter; Shale, Charles; Baber, Jonathan; Rozemuller, Erik; Cuppen, Edwin
(2023) Nature Genetics, volume 55, issue 5, pp. 820 - 831
(Article)
Abstract
Studies have characterized the immune escape landscape across primary tumors. However, whether late-stage metastatic tumors present differences in genetic immune escape (GIE) prevalence and dynamics remains unclear. We performed a pan-cancer characterization of GIE prevalence across six immune escape pathways in 6,319 uniformly processed tumor samples. To address the complexity ... read more
Download/Full Text
Open Access version via Utrecht University Repository Publisher version
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: Humans, Mutation, Neoplasms, Second Primary, Journal Article, Research Support, Non-U.S. Gov't
DOI: https://doi.org/10.1038/s41588-023-01367-1
ISSN: 1061-4036
Publisher: Nature Publishing Group
Note: Funding Information: This publication and the underlying study have been made possible partly on the basis of the data that the Hartwig Medical Foundation and the Center of Personalised Cancer Treatment have made available to the study. We thank A. Van Hoeck and A. G. Perez for critical reading of the manuscript and their valuable input. We also thank A. Van Hoeck for assistance in the dataset collection and L. Nyguen for help in the mutational signature extraction. We thank H. W. Lee for technical assistance in the TRACERx dataset processing. The present study makes use of data generated by the TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (TRACERx) Consortium and provided by the UCL Cancer Institute and the Francis Crick Institute. The TRACERx study is sponsored by University College London (UCL), funded by Cancer Research UK and coordinated through the Cancer Research UK and UCL Cancer Trials Centre. We also thank N. McGranahan, O. Pich and C. Puttick for sharing the original HLA-I typing and LOHHLA calls used in their original publication. Finally, we thank W. Mulder, M. Penning and H. Merkens for discussions on LILAC’s orthogonal validation. Funding Information: This publication and the underlying study have been made possible partly on the basis of the data that the Hartwig Medical Foundation and the Center of Personalised Cancer Treatment have made available to the study. We thank A. Van Hoeck and A. G. Perez for critical reading of the manuscript and their valuable input. We also thank A. Van Hoeck for assistance in the dataset collection and L. Nyguen for help in the mutational signature extraction. We thank H. W. Lee for technical assistance in the TRACERx dataset processing. The present study makes use of data generated by the TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (TRACERx) Consortium and provided by the UCL Cancer Institute and the Francis Crick Institute. The TRACERx study is sponsored by University College London (UCL), funded by Cancer Research UK and coordinated through the Cancer Research UK and UCL Cancer Trials Centre. We also thank N. McGranahan, O. Pich and C. Puttick for sharing the original HLA-I typing and LOHHLA calls used in their original publication. Finally, we thank W. Mulder, M. Penning and H. Merkens for discussions on LILAC’s orthogonal validation. Publisher Copyright: © 2023, The Author(s).
(Peer reviewed)